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Background: Microglia are dependent upon colony-stimulating factor 1 receptor (CSF1R) signaling for their survival
in the adult brain, with administration of the dual CSF1R/c-kit inhibitor PLX3397 leading to the near-complete
elimination of all microglia brainwide. Here, we determined the dose-dependent effects of a specific CSF1R
inhibitor (PLX5622) on microglia in both wild-type and the 3xTg-AD mouse model of Alzheimer’s disease.
Methods: Wild-type mice were treated with PLX5622 for up to 21 days, and the effects on microglial numbers
were assessed. 3xTg-AD mice were treated with PLX5622 for 6 or 12 weeks and effects on microglial numbers and
pathology subsequently assessed.
Results: High doses of CSF1R inhibitor eliminate most microglia from the brain, but a 75 % lower-dose results in
sustained elimination of ~30 % of microglia in both wild-type and 3xTg-AD mice. No behavioral or cognitive deficits
were found in mice either depleted of microglia or treated with lower CSF1R inhibitor concentrations. Aged 3xTg-AD
mice treated for 6 or 12 weeks with lower levels of PLX5622 resulted in improved learning and memory. Aβ levels and
plaque loads were not altered, but microglia in treated mice no longer associated with plaques, revealing a role for the
CSF1R in the microglial reaction to plaques, as well as in mediating cognitive deficits.
Conclusions: We find that inhibition of CSF1R alone is sufficient to eliminate microglia and that sustained microglial
elimination is concentration-dependent. Inhibition of the CSF1R at lower levels in 3xTg-AD mice prevents microglial
association with plaques and improves cognition.
Keywords: Alzheimer’s disease, Neuroinflammation, Cognition, TherapeuticsIntroduction
Microglia are the primary immune cell of the central
nervous system (CNS), comprising ~12 % of all cells
found there. They are found ubiquitously throughout
the CNS and function to detect pathogens and insults
and respond to them through complicated physical and
chemical remodeling processes. While microglia are cru-
cial for the protection of the CNS from pathogens, as
well as in clearing up cellular debris following cell death
or minor injuries, they are well studied for their roles in* Correspondence: kngreen@uci.edu
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traumatic brain injuries and stroke [1, 2]. It is generally
thought that microglia mount an initial beneficial re-
sponse, helping to limit damage from injury [3], or
phagocytosing aggregating toxic peptides such as Aβ [4]
and perhaps limiting plaque formation. However, these
initial responses evolve into chronic inflammatory pro-
cesses that may never resolve and can be damaging to
the local brain environment, thus contributing to the
disease/injury process itself [5]. Hence, finding ways to
manipulate microglial function and numbers may offer a
way to treat CNS disorders. To that end, we recently
discovered that treatment of adult mice with PLX3397,
the dual colony-stimulating factor 1 receptor (CSF1R)
and c-kit kinase inhibitor, leads to the near-completerticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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days [6]. Furthermore, microglia remain eliminated for
the duration of treatment, allowing for indefinite micro-
glial elimination from the adult CNS. As CSF1R knock-
out mice are born without microglia [7, 8], and mice
lacking either of its two substrates, CSF1 [9] or IL-34
[10], also have reduced microglial densities; it suggests
that microglia are fully dependent upon CSF1R signaling
for their survival. Here, we describe the effects of a spe-
cific CSF1R inhibitor, PLX5622, on microglial homeosta-
sis in the adult brain. PLX5622 is a potent inhibitor of
CSF1R tyrosine kinase activity (KI = 5.9 nM) with at least
50-fold selectivity over 4 related kinases, and over 100-fold
selectivity against a panel of 230 kinases [11–14]. As pro-
longed microglial elimination may not be translatable to
humans for the extended duration of a neurodegenerative
disease, we have explored the effects of lower, and more
clinically relevant, drug exposures on microglial pheno-
types and animal cognition/behavior in both adult healthy
mice and a mouse model of Alzheimer’s disease.
Methods
Compounds
PLX5622 was provided by Plexxikon Inc. and formulated
in AIN-76A standard chow by Research Diets Inc. at the
doses indicated in the text.
Animal treatments
All rodent experiments were performed in accordance with
animal protocols approved by the Institutional Animal
Care and Use Committee at the University of California,
Irvine (UCI). LPS treatment: LPS (from Escherichia coli
055:B5; Sigma) was dissolved in phosphate buffered sa-
line (PBS) at a concentration of 0.1 mg/ml and admin-
istered intraperitoneally (IP) at a dose of 0.5 mg/kg
body weight. Following any treatments, mice were sacri-
ficed and brains isolated. One-half of the brain was fixed
in 4 % paraformaldehyde and the other half was snap
frozen on dry ice and stored at −80 °C until analysis.
Thioflavin S staining
Brain sections were incubated in 0.5 % thioflavin S solution
in 50 % ethanol for 10 min, rinsed twice in 50 % ethanol,
then rinsed twice in water. Sections were visualized with
a confocal microscope. Average plaque number, size, and
percentage distribution of size were obtained using
Bitplane Imaris 7.4 software.
Confocal microscopy
Fluorescent immunolabeling followed a standard indirect
technique (primary antibody followed by fluorescent
secondary antibody) as described in [15]. Cell counts and
sizes were obtained by scanning regions at 10× at com-
parable sections in each animal, followed by automaticanalyses using Bitplane Imaris 7.4. Acid pretreatments
were used for 6e10 detection. The following antibodies
were used: anti-IBA1 (1:1000; Wako), anti-GFAP (1:1000;
Dako), anti-6e10 (1:1000; Chemicon), and anti-S100
(1:1000; Abcam). Stained tissue was mounted on slides and
cover slipped with Dapi Fluoromount-G (SouthernBiotech).Aβ ELISA
Aß1–40 and Aß1–42 were measured using a sensitive
sandwich ELISA system as previously described [16].mRNA extraction and real-time PCR
Total mRNA was extracted from frozen half brains, cDNA
was synthesized, and real-time PCR (RT-PCR) was per-
formed with commercially available kits for TNFα (F,
5′-GGTGCCTATGTCTCAGCCTCTT; R, 5′-GCCATA
GAACTGATGAGAGGGAG) and IL1β (F, 5′-TGGACC
TTCCAGGATGAGGACA; R, 5′- GTTCATCTCGGAG
CCTGTAGTG). CT values were normalized to GAPDH
and expressed as a percent of control. Two-month-old
wild-type mice were treated with PLX5622 (1200 mg/kg
chow; n = 4) or vehicle (n = 4) for 14 days. On day 14, half
of the mice in each dietary group were administered
with either LPS (0.5 mg/kg) or an equivalent volume of
PBS via IP injection (n = 4 per group). Mice were eutha-
nized 6 h after injection, perfused with PBS, and their
brains were collected and snap frozen with dry ice for
RNA extraction.Behavioral testing
Open field: Open-field testing was employed as a meas-
ure of anxiety as well as motor ability. Mice were placed
in an opaque white box (33.7 cm L × 27.3 cm W×
21.6 cm H) for 5 min while their behavior was video-
recorded. The amount of time spent in the center versus
the perimeter of the box and motor readouts (distance
moved and velocity) were obtained. Barnes maze: Mice
were tested in the Barnes maze (table diameter 122 cm,
40 holes with diameter 4.8 cm, elevated 140 cm above
the ground) for 5 days (acquisition, 4 days, 2 trials/day,
maximum 120 s/trial, 15 min intertrial interval; 24-hr
probe, 1 day, 1 trial, maximum of 120 s), as a measure
of spatial learning and memory. Latency to find the tar-
get and enter the target box (i.e., escape latency) was re-
corded live each day of acquisition, while latency to find
the target and number of errors prior to finding the target
was recorded live on the probe day. Morris water maze:
Hidden platform Morris water maze (MWM) training
and testing were conducted as described previously [17].
Novel object and place recognition tasks: Novel object and
place recognition training and testing were conducted as
described previously [18].
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Aβ42 was oligomerized as previously described [19].
One micromolar of this stock was added to BV2 cell
cultures 24 h before the assay to create Aβ-
stimulated enriched media. This media was used as a
chemoattractant in the ChemoTx® Chemotaxis Sys-
tem. BV2 cells were treated either 15 min or 24 h
before the assay with 1- or 10 μM of PLX5622 in
DMSO, and 50,000 cells were added to each well onFig. 1 CSF1R inhibition eliminates microglia from the adult brain. Two-mon
PLX5622 for 7 or 21 days. a IBA1 immunofluorescent staining was performe
confocal images are shown for 7 and 21 days of treatment. b Quantificatio
IMARIS software. c–f 2 month-old wild-type mice were treated with 300 or
administered via IP (0.5 mg/kg). mRNA for TNFα and IL-1β was measured an
with PBS or LPS, showing a marked increase in both inflammatory markers
in PLX5622-treated groups (d). e, f Inflammatory markers were measured v
LPS injection; treatment with 1200 mg/kg PLX5622 treatment lowered the
300 mg/kg PLX5622 had no significant effect on elevated levels of LPS-in
indicates a statistical trend (p < 0.1), via two-way ANOVA with post hoc pthe assay plate. Cells were allowed to migrate for
3 h. Migrated cells were stained with H+E and
counted.
Statistics
Appropriate statistical analyses were carried out to
determine significance between groups using unpaired
Student’s t test for comparisons between two groups, one-
way ANOVA for multiple comparisons, with Newman-th-old wild-type mice were treated with vehicle, 300- or 1200 mg/kg
d on vehicle, 300 and 1200 mg/kg treated animals; representative 10×
n of the number of IBA1+ cells for all groups was performed using
1200 mg/kg PLX5622 or vehicle for 14 days, and LPS or PBS was then
d normalized to GAPDH in control and PLX5622-treated mice injected
in control groups injected with LPS and a dampened response to LPS
ia MSD® Multi-Spot Assay, revealing increases in nearly all markers with
LPS-induced elevated levels of IFNγ, IL-10, and IL-1β. Treatment with
duced elevated levels of markers. *Indicates significance (p > 0.05), #
aired contrasts. Error bars indicate SEM
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havioral data and MSD® Multi-Spot Assay data were ana-
lyzed using a two-way ANOVA (treatment x day of testing
and diet x injection, respectively) using the MIXED pro-
cedure of the Statistical Analysis Systems software (SAS
Institute Inc.). For behavioral data, “mouse” was a random
effect and “day of testing” was a repeated measure. Post
hoc paired contrasts were used to examine biologically
relevant interactions from the two-way ANOVA.Fig. 2 CSF1R inhibition does not alter cognition or behavior in adult mice.
or 1200 mg/kg PLX5622 for 14 days, and behavioral analyses were conduc
measured across groups in the open-field test in distance traveled, veloci
No differences were measured across groups in the Barnes maze in ac
indicate SEMResults
The selective CSF1R inhibitor PLX5622 reduces microglial
numbers in the adult brain
To determine the effects of specific CSF1R inhibition on
microglial numbers in the adult brain, 2-month-old
wild-type mice were treated with vehicle or PLX5622 at
300- or 1200 mg/kg in chow for 7 or 21 days (n = 3 per
group). Mice were sacrificed and their brains fixed and
sectioned and then stained with the microglial markera Two-month-old wild-type mice were treated with either vehicle, 300
ted using an open-field test and Barnes maze. b–e No differences were
ty, time spent in open arena, or time spent in edge of arena. f–g
quisition of time to find escape hole or in probe trial. Error bars
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cortex were taken with a 10× objective, and automated
cell counts were then performed. Quantification revealed
that 7 and 21 days of treatment with 300 mg/kg chow
caused a sustained ~30 % reduction in microglia num-
bers. However, treatment with 1200 mg/kg chow led to
rapid and robust reductions in microglial numbers, with
an 80 % reduction seen within 7 days of treatment.
Treatment with either PLX5622 or PLX3397 eliminates
microglia, but the former is able to do so without alsoFig. 3 Microglial repopulation following microglial elimination with PLX562
were treated with 1200 mg/kg chow PLX5622 or vehicle for 7 days. The PL
3 days later. a–c IBA1/IB4 staining in control, 7 days treated with PLX5622, and
region shown. d–f Whole brain sections were scanned and each IBA1+ ce
dot superimposed over each IBA1+ cell as a visual aid. g Quantification o
hoc Newman-Keuls multiple comparison test. Error bars indicate SEMinhibiting c-kit. These results show that specific inhib-
ition of the CSF1R alone is sufficient for elimination of
microglia from the adult CNS. Additionally, we can tightly
control the amount of microglial elimination by changing
the CSF1R inhibitor dose—300 mg/kg chow results in sus-
tained 30 % elimination, and thus, elimination is not an all
or nothing event but something that can be modulated.
We next explored the response of the microglia-depleted
brain to systemically administered LPS. Two-month-
old wild-type mice were treated with PLX5622 (300 or2 and subsequent PLX5622 withdrawal. Two-month-old wild-type mice
X5622 was then removed and the number of microglia was assessed
7 days treated with PLX5622 with 3 days recovery, with hippocampal
ll counted. Representative brain sections are shown, with a white
f d–f. *Indicates significance (p > 0.05) via one-way ANOVA with post
Fig. 4 (See legend on next page.)
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Fig. 4 Lower doses of PLX5622 improve cognition in aged 3xTg-AD mice. Fifteen-month-old 3xTg-AD mice were treated for either 6 weeks or
3 months with vehicle or 300 mg/kg PLX5622. a–b Animals treated for 6 weeks were assessed using novel place and novel object recognition
tasks. Treated mice showed a significant improvement in place recognition as compared to untreated 3xTg-AD mice, but no differences were
measured between groups in novel object recognition. c–k Animals treated for 3 months were assessed using Morris water maze, novel place
recognition, and novel object recognition. c–e Morris water maze. Treated mice had significantly faster escape latencies on days 6 and 7 of Morris
water maze training and trended towards a faster latency to reach platform and increased platform crosses during the probe trial. f, g Treated
mice showed significantly improved place recognition as compared to control mice, but no differences were shown between groups in novel
object recognition. h–k No differences in open field were detected in either distance traveled (h), average velocity (i), the time spent in the
center of the arena (j), or in the time spent in the perimeter of the arena (k). *Indicates significance (p < 0.05) by unpaired Student’s t test.
Error bars indicate SEM
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LPS was then administered (IP; n = 4 per group). Mice
were sacrificed 6 h later, and mRNA and protein levels of
inflammatory markers were measured from brain tissue
via real-time PCR (normalized to the housekeeping
gene GAPDH) and MSD® Multi-Spot Assay, respectively
(Fig. 1c–f). As expected, LPS treatment robustly increased
RNA levels of both TNFα and IL-1β message in microglia-
intact animals and increased protein levels of nearly all in-
flammatory markers examined, with the exception of IL-4.
Levels of TNFα and IL-1β mRNA in response to LPS in
the 1200 mg/kg PLX5662-treated mice were significantly
diminished (Fig. 1d), and protein levels of IFN-γ, IL-10,
and IL-1β in response to LPS were also decreased with
1200 mg/kg PLX5622 treatment; however, no changes in
inflammatory markers were seen with 300 mg/kg
PLX5622 treatment (Fig. 1e, f ). Interestingly, although the
mRNA levels for TNFα decreased with 1200 mg/kg
PLX5622 treatment in response to LPS, TNFα protein
levels were not reduced. Although apparently contradict-
ory, these data likely reflect the ability of TNFα to cross
the BBB from the periphery [20]. Indeed, plasma TNFα
levels in these samples were highly and significantly ele-
vated in all LPS-injected groups (data not shown).Microglial depletion does not affect behavior or learning
and memory
Two-month-old wild-type mice were treated with either
vehicle or 300- or 1200 mg/kg chow PLX5622 for 14 days,
and behavioral analyses were then conducted (n = 10 per
group) (Fig. 2a–g). Mice were first tested in open field
analyses. No differences were seen in mice with either
dose of PLX5622 in the distance traveled (Fig. 2b), velocity
(Fig. 2c), time spent in the open area (Fig. 2d), or time
spent in the edge of the arena (Fig. 2e), compared to
vehicle-treated mice. Next, mice were tested on Barnes
maze—a hippocampal-dependent learning and memory
task. Again, no differences were found between any of
the groups on acquisition of the time to find the escape
hole (Fig. 2f ) or in the probe trial conducted 24 h after
the last training session (Fig. 2g). Thus, depletion of
microglia with PLX5622 does not induce any deficits inthese particular tasks, in agreement with our previous
data [6].
Microglial elimination with PLX5622 followed by drug
removal results in rapid repopulation of the CNS
We previously showed that elimination of microglia via
treatment with, and subsequent removal of, the CSF1R/
c-kit inhibitor PLX3397 led to rapid repopulation of the
microglial tissue. In this previous study, we found that
microglial repopulation is not due to infiltration of per-
ipheral cells and rather occurs from CNS resident non-
myeloid cells [6]. To determine the involvement of c-kit
in this process, we treated 2-month-old wild-type mice
for 7 days with 1200 mg/kg chow PLX5622, which does
not inhibit c-kit, and then withdrew PLX5622 for 3 days
(n = 4 per group). Seven-day treatment eliminated >95 %
of microglia throughout the CNS (Fig. 3a–e, quantified
in G), as determined via the number of IBA1+ cells per
brain section. Three days following drug withdrawal, re-
population of the CNS had occurred (Fig. 3f ), showing
that repopulation is not dependent on c-kit signaling
and that elimination of microglia via CSF1R inhibition
alone is sufficient to trigger the repopulation events. Re-
populating cells were also detected with the lectin IB4,
consistent with our prior observations [6].
PLX5622 improves cognition in aged 3xTg-AD mice
The AD brain is not only characterized by the presence
of plaques and tangles but also by a chronic microglia-
evoked neuroinflammatory response. Chronic neuroin-
flammation is harmful to the local brain environment
and can be both synapto- and neurotoxic [21]. Fifteen-
month-old 3xTg-AD mice, which develop both Aβ and
tau pathologies as they age [22], were treated for either
6 weeks (n = 8 per group) or 3 months with 300 mg/kg
chow PLX5662 or vehicle (n = 10 per group). At the end
of this period, we conducted cognitive testing, followed
by assessment of pathology. 3xTg-AD mice treated for
6 weeks were tested on novel place and novel object
recognition, tasks that test hippocampal- and cortical-
dependent memory, respectively, that rely on a rodent’s
preference to explore a novel object or object location
over the familiar one [23]. 3xTg-AD mice treated with
Fig. 5 (See legend on next page.)
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Fig. 5 Lower-dose CSF1R inhibition partially reduces microglia numbers. The brains of 3 months 3xTg-AD-treated mice were examined for effects
of PLX5622 on pathology. a–d IBA1 immunofluorescent staining was performed and representative 10× images are shown of control and treated
hippocampus and thalamus. e IBA1+ cell counts revealed a reduction by 30 % in the treated groups. f, g IBA1+ cells in treated brains are larger
but have reduced staining intensity as compared to 3xTg-AD untreated mice. h Immunofluorescent staining for the astrocytic markers GFAP (red),
S100 (green), and plaques with 6E10 (blue), with the hippocampal region shown. i Quantification of the number of GFAP+ cells in the hippocampal
sub-field. j Inflammatory profiling of whole brain homogenates shows significant increases in CXCL1 and TNFα but not Il-1β or Il-6. *Indicates
significance (p < 0.05) by unpaired Students t test. Error bars indicate SEM
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from untreated control 3xTg-AD mice (Fig. 4a), which
were unable to discriminate between the objects. No dif-
ferences in novel object were seen; both groups were un-
able to discriminate between the two objects (Fig. 4b).
Having shown improvements after 6 weeks of treatment,
we then set about a more extensive battery of behavioral
tasks in mice treated with PLX5622 for 3 months. Mice
were first tested on the Morris water maze, another
hippocampal-dependent task that tests learning and mem-
ory [24]. 3xTg-AD mice treated with PLX5622 tended to
have faster escape latencies than untreated mice across all
days tested, with significant improvements seen on days 6
and 7 (Fig. 4c). A probe trial was conducted 24 h after
the last training day, with the hidden platform removed.
PLX5622-treated 3xTg-AD mice trended towards a faster
latency to get to the platform location and increased plat-
form crosses, but did not achieve significance (Fig. 4d
and e). Next, mice were tested with novel place recogni-
tion and novel object recognition. Untreated 3xTg-AD
mice showed no preference for either the familiar or
novel place, suggesting a deficit. However, PLX5622-
treated 3xTg-AD mice showed a clear preference for
the novel place, indicating improvement (Fig. 4f ), as
with the 6-week treatment. No significant differences
were seen in the novel object recognition task (Fig. 4g).
The two groups of mice were also evaluated in the open-
field test (Fig. 4h–k). No differences in the distance
traveled or average velocity were seen, nor were there any
changes in neophobic behaviors as shown by similar dura-
tions of time spent in both the center and perimeter of
the arena.
Lower-dose PLX5622 treatment partially reduces
microglial numbers
We next examined the brains of the 3xTg-AD mice treated
for 3 months to evaluate the effects of PLX5622 on glial
cells and pathology. Immunohistochemistry revealed 30 %
reductions in microglial numbers in areas not adjacent to
plaque loads (Fig. 5a–e), in line with the data in Fig. 1a, b,
showing that we can achieve sustained targeted reductions
in brainwide microglia, rather than just total elimination.
Microglia in the PLX5622-treated mice had significantly
larger cell sizes (Fig. 5f), in line with our previous findings
[6], and also reduced IBA1 staining intensity (Fig. 5g).Immunostaining for the astrocytic markers GFAP and
S100 showed robust astrogliosis associated with plaques
(Fig. 5h), but PLX5622 treatment did not alter this re-
sponse or the overall number of GFAP/S100+ cells present
within the hippocampus (Fig. 5i). Inflammatory profiling
using multiplex technology in soluble brain homogenates
showed no changes in Il-1β or Il-6 with treatment, in
line with the data obtained following LPS injections
(Fig. 1e, f ), but significant increases were found in CXCL1
and TNFα (Fig. 5j). Markers IFN-γ, Il-10, Il-12p70, Il-2,
Il-4, and Il-5 were below detection levels.
Lower-dose PLX5622 treatment prevents microglial
association with plaques
Sandwich ELISA for Aβ40 and Aβ42 in the soluble and
insoluble fractions revealed no significant differences
between the PLX5622-treated group and the controls
(Fig. 6a, b). Thio-S staining revealed abundant dense
core plaques in all animals, particularly in the subiculum
(Fig. 6c, d). Quantification of number of plaques (Fig. 6e),
average plaque size (Fig. 6f ), or distribution of small,
medium, or large plaques (Fig. 6g), revealed no changes
with treatment.
However, stark differences were seen in the microglia
that are associated with plaques—in vehicle-treated animals,
microglia were densely packed around plaques and dis-
played an activated morphology (Fig. 7a–c). Mice treated
with PLX5622 showed comparable plaque load, but micro-
glia were not associated with plaques to the same extent
(Fig. 7d–f), suggesting that low doses of PLX5622 do not
fully eliminate microglia but alter their response to inflam-
matory stimuli, such as plaques. Indeed, closeup z-stacks
showed a clear association of microglia with plaques in un-
treated 3xTg-AD mice (Fig. 7g–i) but a lack of association
in PLX5622-treated mice (Fig. 7j–l). Quantification of
the number of microglia associated with a plaque and
normalized to plaque diameter revealed a 70 % reduction
in microglia associated with plaques. To explore the possi-
bility that this lower dose of CSF1R inhibitor could be se-
lectively killing plaque-associated microglia, we performed
immunostaining for active caspase-3, as an indicator of
cell death. However, no increased microglial cell death
was seen in PLX5622-treated mice in areas adjacent to
plaques (data not shown). This suggests that the reduction
in the number of microglia associated with plaques is due
Fig. 6 Lower-dose CSF1R inhibition does not alter Aβ or Tau levels. a, b Sandwich ELISA in soluble and insoluble fraction revealed no significant
differences in Aβ40 or Aβ42 between groups. c, d Thioflavin-S staining was performed, revealing plaques in both control and treated groups. Of
the subiculum, 10× images are shown. e–g Analysis of plaques revealed no significant difference between treated and untreated brains in average
number of plaques, average plaque size, or distribution of large, medium, and small plaques. h–k Immunostaining for total human tau with
HT7 (h, i) and AT8 tau (j, k) reveals no significant differences in tau levels with PLX5622 treatment. Error bars indicate SEM
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that susceptible plaque-associated microglia are already
dead and no further cells are going through the cell
death process at this point.3xTg-AD mice also show progressive tau pathology
as they age, including somatodendritic accumulation of
human tau and hyperphosphorylation [25]. Quantification
of total human tau accumulation within somatodendritic
Fig. 7 Chronic lower-dose CSF1R inhibition prevents microglia associating with plaques. Immunofluorescent staining was performed on 3 months
treated and control 3xTg-AD mice for 6E10, which recognizes Aβ plaques and IBA1. a–f Representative 10× images are shown of control and
treated mice. g–l Representative 63× images are shown of control and treated mice, centered on an area dense with plaques. m Quantification
of the number of microglia associated with a plaque and normalized to plaque diameter revealed a 70 % decrease in treated animals as compared to
untreated animals. *Indicates significance (p < 0.05) by unpaired Students t test. Error bars indicate SEM
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Fig. 8 PLX5622 inhibits chemotaxis of BV-2 cells in response to Aβ-oligomer-stimulated enriched media. Chemotaxis was measured by
counting migrated BV2 cells in response to Aβ-stimulated enriched media or control enriched media. BV2 cells were treated with 0-, 1-, or 10 μM
PLX5622 either 15 min or 24 h before the assay was conducted. All treated cells exhibited significantly reduced cell migration in response to
the Aβ-stimulated enriched media
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with treatment, nor tau phosphorylated at S202/T205
(Fig. 6h–k).
PLX5622 prevents chemotaxis of BV2 cells in response to
Aβ-stimulated enriched media
In order to determine the mechanism behind the reduced
microglial association with Aβ plaques, we conducted a
chemotaxis assay on BV2 microglial cells treated with
1- or 10 μM PLX5622 (equivalent to a low- and high-
dose of PLX5622, respectively) for 15 min or 24 h (n = 5
per group). Aβ-oligomer-stimulated enriched BV2 media
was used as a chemoattractant in a ChemoTx® Chemotaxis
System, and chemotaxis was measured by BV2 cell migra-
tion towards the media. All treated groups with PLX5622
showed significantly reduced cell migration to the Aβ-
enriched media, indicating an impaired ability to respond
to the chemoattractant signals produced by Aβ-enriched
BV2 media, supporting the lack of microglial association
with plaques in the treated brain (Fig. 8).
Discussion
We previously discovered that administration of the dual
CSF1R/c-kit kinase inhibitor PLX3397 led to the rapid
elimination of >99 % of all microglia from the CNS within
7–21 days [6]. CSF1R knockout mice are born without
microglia [7, 8], suggesting that signaling through this re-
ceptor is crucial for the development of microglia. These
mice are born with developmental defects and die a few
weeks after birth, making them an unsuitable model
for studying microglial function. The CSF1R has two
endogenous ligands—CSF1 and IL-34 [10]. Mice lacking
either one of these ligands are also born with lower dens-
ities of microglia throughout the CNS [9], and diminished
numbers of microglia are maintained throughout life.Thus, the CSF1R seems crucial for microglial development
and also population maintenance, as well as microglial pro-
liferation during responses to neurodegeneration [26]. As
our previous study inhibited both CSF1R and c-kit, we
set out to determine if inhibition of CSF1R alone was
sufficient to eliminate microglia from the adult brain.
Our results with the specific CSF1R inhibitor PLX5622
clearly show that inhibition of CSF1R alone is sufficient
to eliminate microglia, and therefore, microglia require
CSF1R signaling for their survival. Crucially, we found
that lower doses of CSF1R inhibitor could lead to sus-
tained elimination of a percentage of microglia, thus
allowing us to tightly control the number of surviving
microglia through different concentrations of CSF1R
inhibitors. This approach may be more practical for clin-
ical applications, where complete elimination of microglia
for extended periods of time may be undesirable. Thus,
we further sought to establish the effects and benefits of
this paradigm in both healthy and diseased mice.
We previously demonstrated that elimination of micro-
glia with PLX3397 had no detrimental effects on locomo-
tion, cognition, or behavior, despite mice being depleted of
microglia for up to 2 months [6]. This was an unexpected
finding, as a role for microglia in synaptic sculpting [5, 27]
and neuronal communication [28] is emerging. However,
we confirm our prior results and show that elimination of
microglia with PLX5622 leads to no discernable defi-
cits in behavior or learning and memory in the tasks
tested. Likewise, lower levels of CSF1R inhibitor treat-
ment had no effects on behavior or learning in wild-
type mice. As prolonged near-complete microglial
elimination, which is achieved with the higher doses of
CSF1R inhibitors, may not be translatable for the full
duration of a neurodegenerative disease, lower levels of
CSF1R inhibitors may offer a chronic option for the
Dagher et al. Journal of Neuroinflammation  (2015) 12:139 Page 13 of 14treatment of neuroinflammation. To that end, we also
tested chronic treatment with the lower dose of PLX5622
in aged 3xTg-AD mice. As with wild-type mice, this lower
dose resulted in sustained elimination of only ~30 % of
microglia, even over a 3 month period. Strikingly, how-
ever, this treatment strongly diminished the association
between microglia and plaques; untreated 3xTg-AD mice
have high plaque burdens and all plaques are tightly sur-
rounded by numerous microglia, yet treated 3xTg-AD
mice have the same plaque burdens, but their microglia
no longer surround them. Despite this lack of microglia
associated with plaques, Aβ levels and plaque numbers
and sizes were not altered, suggesting that microglia sur-
rounding plaques are not actively restricting their growth
or formation, consistent with previous findings [29].
Inflammatory status has been linked to cognitive defi-
cits in AD patients [30], with anti-inflammatory treatments
improving cognition in transgenic models of the disease
[18]. Here, we found that targeting microglia with CSF1R
inhibitors also led to improvements in cognition in the
3xTg-AD mice. We find that low dose treatments reduce
brain microglial number by 30 %, but this does not dimin-
ish the overall levels of inflammatory markers. In line with
these results, we explored the inflammatory response to
LPS in wild-type mice with the same 300 mg/kg PLX5622
treatment and also found no significant effects of treat-
ment. Moreover, we actually found increases in the
levels of the typically proinflammatory markers TNFα
and CXCL1 with treatment in the 3xTg-AD mice. Though
seemingly counterintuitive, these results direct our attention
towards other possible, non-inflammatory, mechanisms of
action of PLX5622 treatment for improved behavior, poten-
tially by acting as a “microglial shaper.” Notably, we find that
this treatment prevents the association of microglia with
plaques, suggesting that CSF1R inhibition alters the micro-
glial phenotype and results in behavioral improvements.
While we cannot determine the relative contributions
of modest reductions in microglial numbers vs. preven-
tion of microglial association with plaques, treatment
with 300 mg/kg PLX5622 ultimately results in improved
cognition. Although average cell area was increased in sur-
viving microglia, which we have found to be a stereotyp-
ical response to CSF1R inhibition [6], we found average
IBA1 staining intensity to be reduced in PLX5622-treated
mice. As differential levels of IBA1 expression have also
been linked to migratory function [31], the reduction in
IBA1 staining intensity supports the hypothesis that
microglial function is altered with 300 mg/kg PLX5622
treatment.
Of interest, recent studies investigating the effects of
the AD-associated TREM2 gene on AD pathology found
that heterozygous loss of one or two TREM2 alleles al-
tered the microglial response to Aβ plaques [32–34],
paralleling the effects of lower doses of PLX5622. CSF1signaling can be regulated by TREM2 [35, 34], which
could suggest that the effects of TREM2 on microglia in
the AD brain may be partly mediated by the CSF1 sig-
naling cascade. It may be that association and chemo-
taxis of microglia to Aβ deposits are protective in the
initial stages of the disease when the microglia can help
clear the aggregates from the brain, but that preventing
this association at later stages alters the chronic neuroin-
flammatory response and becomes beneficial, as we
describe here.
Conclusions
We find that inhibition of CSF1R alone is sufficient to
eliminate microglia but the level of elimination is both
dose-dependent and chronically sustainable. Elimination
of microglia does not impair behavior or cognition in
wild-type mice. Of disease and translational relevance,
lower dose inhibition of the CSF1R in 3xTg-AD mice pre-
vents microglial association with plaques and improves
cognition.
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